Regulus Therapeutics (NASDAQ:RGLS) Stock Price Crosses Above 200-Day Moving Average – Time to Sell?

Regulus Therapeutics Inc. (NASDAQ:RGLS) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.46 and traded as high as $1.84. Regulus Therapeutics shares last traded at $1.78, with a volume of 833,887 shares.

Wall Street Analysts Forecast Growth

RGLS has been the subject of several research reports. Wells Fargo & Company raised Regulus Therapeutics from an “equal weight” rating to an “overweight” rating and increased their target price for the stock from $3.00 to $6.00 in a research report on Thursday, March 27th. HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Regulus Therapeutics in a research note on Friday, March 14th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $28.00 price objective on shares of Regulus Therapeutics in a report on Monday, March 17th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $12.75.

Regulus Therapeutics Price Performance

The firm has a market capitalization of $117.91 million, a PE ratio of -1.66 and a beta of 1.03. The business has a 50-day simple moving average of $1.42 and a 200-day simple moving average of $1.46.

Regulus Therapeutics (NASDAQ:RGLS) last released its quarterly earnings results on Thursday, March 20th. The biopharmaceutical company reported ($0.20) EPS for the quarter, hitting analysts’ consensus estimates of ($0.20). During the same quarter in the previous year, the firm earned ($0.40) EPS. On average, research analysts expect that Regulus Therapeutics Inc. will post -0.88 earnings per share for the current year.

Insider Buying and Selling at Regulus Therapeutics

In other news, VP Christopher Ray Aker sold 38,547 shares of the firm’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $1.26, for a total value of $48,569.22. Following the completion of the sale, the vice president now owns 54,634 shares of the company’s stock, valued at $68,838.84. This trade represents a 41.37 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Preston Klassen sold 31,445 shares of the company’s stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $1.26, for a total transaction of $39,620.70. Following the transaction, the insider now owns 36,055 shares in the company, valued at approximately $45,429.30. This trade represents a 46.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 223,998 shares of company stock valued at $282,237 in the last ninety days. Corporate insiders own 4.35% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Millennium Management LLC boosted its stake in shares of Regulus Therapeutics by 69.7% during the 4th quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company’s stock worth $3,464,000 after acquiring an additional 900,743 shares in the last quarter. Octagon Capital Advisors LP increased its position in shares of Regulus Therapeutics by 13.7% in the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company’s stock valued at $7,661,000 after buying an additional 585,101 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in Regulus Therapeutics in the 3rd quarter worth $204,000. JPMorgan Chase & Co. increased its holdings in Regulus Therapeutics by 141.2% in the 4th quarter. JPMorgan Chase & Co. now owns 190,457 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 111,485 shares in the last quarter. Finally, Velan Capital Investment Management LP purchased a new position in Regulus Therapeutics during the fourth quarter valued at $111,000. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.